Diagnostics & Research Stocks: Companies & Metrics

Browse 46 diagnostics & research stocks with financial metrics and performance data (Healthcare sector).

Industry market cap: $935.38B
Cap-weighted, today: −1.43%
Cap-weighted, 1 year: +35.65%
Advancing / declining today: 15 / 30

Diagnostics & Research Stocks

46 stocks in the diagnostics & research industry. Click column headers to sort.

#
1	TMO	Thermo Fisher Scientific Inc.	$676.54	$251.00B	$46.34B	$6.98B	$18.62	2.46M
2	DHR	Danaher Corporation	$229.75	$162.57B	$25.11B	$4.00B	$5.63	4.85M
3	NTRA	Natera, Inc.	$401.37	$57.51B	$2.71B	-$192.35M	−$1.38	1.72M
4	A	Agilent Technologies, Inc.	$173.89	$49.21B	$7.37B	$1.44B	$5.07	2.41M
5	IQV	IQVIA Holdings Inc.	$278.32	$46.56B	$16.98B	$1.38B	$8.08	1.49M
6	IDXX	IDEXX Laboratories, Inc.	$566.76	$44.95B	$4.55B	$1.14B	$14.22	513.55K
7	WAT	Waters Corporation	$455.59	$44.74B	$5.82B	-$54.79M	−$0.68	832.75K
8	ILMN	Illumina, Inc.	$269.40	$41.22B	$4.49B	$825.00M	$5.37	3.75M
9	MTD	Mettler-Toledo International Inc.	$1,684.64	$33.97B	$4.13B	$905.61M	$44.44	216.73K
10	DGX	Quest Diagnostics Incorporated	$243.28	$27.25B	$11.56B	$1.06B	$9.46	1.15M
11	LH	Labcorp Holdings Inc.	$329.93	$27.05B	$14.35B	$1.00B	$12.08	731.12K
12	GH	Guardant Health, Inc.	$162.94	$21.65B	$1.18B	-$453.44M	−$3.50	1.85M
13	MEDP	Medpace Holdings, Inc.	$653.96	$18.81B	$2.78B	$491.50M	$16.89	307.96K
14	RVTY	Revvity, Inc.	$157.36	$17.57B	$2.88B	$231.62M	$2.06	2.10M
15	CRL	Charles River Laboratories International, Inc.	$339.66	$16.31B	$4.00B	-$238.46M	−$4.88	1.09M
16	ICLR	ICON Public Limited Company	$185.57	$14.36B	$8.29B	$42.34M	$0.54	994.28K
17	QGEN	Qiagen N.V.	$50.22	$10.44B	$2.10B	$409.32M	$1.97	3.99M
18	TWST	Twist Bioscience Corporation	$135.47	$8.45B	$431.80M	-$136.72M	−$2.23	2.92M
19	BLLN	BillionToOne, Inc.	$105.68	$5.75B	$397.41M	$37.71M	$0.79	581.14K
20	RDNT	RadNet, Inc.	$70.26	$5.53B	$2.27B	-$21.12M	−$0.28	643.44K
21	GRAL	GRAIL, Inc.	$127.06	$5.48B	$165.26M	-$391.59M	−$9.75	1.33M
22	SHC	Sotera Health Company	$18.13	$5.22B	$1.22B	$163.48M	$0.57	2.03M
23	ADPT	Adaptive Biotechnologies Corporation	$24.41	$3.90B	$308.08M	-$63.85M	−$0.40	2.32M
24	VCYT	Veracyte, Inc.	$46.04	$3.78B	$561.90M	$114.48M	$1.41	1.40M
25	CDNA	CareDx, Inc.	$69.16	$3.56B	$458.09M	-$114.92M	−$2.21	1.40M
26	WGS	GeneDx Holdings Corp.	$67.14	$1.99B	$454.43M	-$106.36M	−$3.64	773.61K
27	PSNL	Personalis, Inc.	$15.82	$1.67B	$69.67M	-$107.18M	−$1.10	2.34M
28	OPK	OPKO Health, Inc.	$1.63	$1.23B	$587.89M	-$72.89M	−$0.10	4.45M
29	CSTL	Castle Biosciences, Inc.	$33.15	$1.01B	$357.28M	-$19.41M	−$0.65	365.14K
30	FLGT	Fulgent Genetics, Inc.	$19.99	$559.82M	$323.93M	-$84.38M	−$2.80	305.84K
31	MYGN	Myriad Genetics, Inc.	$5.76	$546.05M	$806.60M	-$112.60M	−$1.20	2.92M
32	NEO	NeoGenomics, Inc.	$16.39	$428.86M	$766.29M	-$51.88M	−$0.67	2.26M
33	PRE	Prenetics Global Limited	$16.57	$286.10M	$142.56M	-$67.61M	−$4.21	193.74K
34	BDSX	Biodesix, Inc.	$23.94	$246.49M	$102.94M	-$27.76M	−$3.13	92.84K
35	XGN	Exagen Inc.	$7.48	$180.75M	$71.12M	-$18.92M	−$0.82	351.42K
36	BNR	Burning Rock Biotech Limited	$13.30	$144.44M	$75.02M	-$10.20M	−$1.24	38.93K
37	IMDX	Insight Molecular Diagnostics Inc.	$2.84	$104.37M	$1.67M	-$49.36M	−$1.46	316.89K
38	MBAI	Check-Cap Ltd.	$2.05	$44.03M	$0.00	-$25.15M	−$4.30	20.03K
39	PRPO	Precipio, Inc.	$20.61	$36.84M	$26.79M	-$1.22M	−$0.71	73.58K
40	QUCY	Quantum Cyber N.V.	$1.02	$18.21M	$250.36K	-$23.96M	−$2.03	453.16K
41	NDRA	ENDRA Life Sciences Inc.	$4.78	$11.83M	$0.00	-$7.49M	−$5.38	29.31K
42	MDXH	MDxHealth SA	$0.18	$9.64M	$136.69M	-$47.18M	−$0.92	1.19M
43	XWEL	XWELL, Inc.	$0.68	$5.80M	$28.28M	-$23.42M	−$3.41	46.80K
44	ADVB	Advanced Biomed Inc.	$3.46	$4.33M	$127.64K	$5.28M	$4.66	35.24K
45	ISPC	iSpecimen Inc.	$0.83	$1.16M	$466.30K	-$11.42M	−$21.82	309.77K
46	BIAF	bioAffinity Technologies, Inc.	$3.17	$1.10M	$5.85M	-$15.19M	−$72.84	2.64M

About the Diagnostics & Research Industry

The Diagnostics & Research industry includes 46 U.S.-listed companies in the Healthcare sector with a combined market capitalization of $935.38B. The largest are Thermo Fisher Scientific Inc. (TMO, $251.00B), Danaher Corporation (DHR, $162.57B) and Natera, Inc. (NTRA, $57.51B), together 50% of the industry's value.

17 of the 46 companies with reported earnings are profitable, and their median P/E ratio is 36.0. 7 of 46 pay a dividend, with a median yield of 0.66% among payers.

Over the past year the median stock is up 17.9%, and 31 of 45 are higher than a year ago. Median revenue growth is 8.4% year over year.

Best 1-year performers

CareDx, Inc. (CDNA)+370.5%
Twist Bioscience Corporation (TWST)+325.6%
Illumina, Inc. (ILMN)+169.5%

Weakest 1-year performers

Highest dividend yields

Qiagen N.V. (QGEN)5.50%
Quest Diagnostics Incorporated (DGX)1.39%
Labcorp Holdings Inc. (LH)0.87%

Profitability

Profitable companies: 17 of 46
Median gross margin: 53.4%
Median net profit margin: -6.4%
Median return on equity: -6.4%

Longest dividend growth streak: Quest Diagnostics Incorporated (DGX), 14 consecutive years.

Frequently Asked Questions About Diagnostics & Research Stocks

How many stocks are in the diagnostics & research industry?

There are 46 publicly traded stocks in the diagnostics & research industry, part of the Healthcare sector.

Which diagnostics & research stocks pay the highest dividend yields?

The highest yields in the diagnostics & research industry are Qiagen N.V. (QGEN, 5.50%), Quest Diagnostics Incorporated (DGX, 1.39%) and Labcorp Holdings Inc. (LH, 0.87%). Quest Diagnostics Incorporated (DGX) has the longest record of dividend increases, 14 consecutive years.

Which diagnostics & research stocks performed best over the past year?

Over the past year the strongest diagnostics & research stocks were CareDx, Inc. (CDNA, +370.5%), Twist Bioscience Corporation (TWST, +325.6%) and Illumina, Inc. (ILMN, +169.5%). The weakest were GeneDx Holdings Corp. (WGS, −46.3%), Myriad Genetics, Inc. (MYGN, −28.4%) and Fulgent Genetics, Inc. (FLGT, −15.4%).

Are diagnostics & research companies profitable?

17 of the 46 diagnostics & research companies with reported earnings are profitable, with a median gross margin of 53.4%, a median net profit margin of -6.4% and a median return on equity of -6.4%.